Loading institutional data...
Loading institutional data...
Held by 1,609 of 5,944 reporting institutions (99th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $516.34 today, the market must believe free cash flow compounds 16.7%/yr for a decade (off $3.3B normalized FCF).
The market's 16.7% is more conservative than its 9-yr track record.
2-stage DCF · 0.25B shares · net debt -$5.1B
mean 50.6% · volatility σ 127% · implied rate exceeded in 5/8 yrs
Central path = implied 16.7%/yr growth; shaded band = ±1σ (127%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Needs granular two-year detail (receivables, PP&E, D&A, SG&A) — not fully reported.
Cash conversion lags reported earnings — watch accruals. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $2.0B buybacks = $2.0B returned on $3.2B FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 21%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit.
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.00B 100.0% | $11.02B 100.0% | $9.87B 100.0% | $8.93B 100.0% | $7.57B 100.0% | $6.21B 100.0% | $4.16B 100.0% | $3.05B 100.0% | $2.49B 100.0% | $1.70B 100.0% |
| Cost of Revenue | $1.65B 13.8% | $1.53B 13.9% | $1.26B 12.8% | $1.08B 12.1% | $904.2M 11.9% | $736.3M 11.9% | $547.8M 13.2% | $409.5M 13.4% | $275.1M 11.1% | $210.5M 12.4% |
| Cost of Products | — | — | — | — | — | — | — | — | $272.7M 11.0% | $206.8M 12.1% |
| Research & Development | — | — | — | — | $3.05B 40.3% | $1.83B 29.5% | $1.75B 42.1% | $1.42B 46.5% | $1.32B 53.2% | $1.05B 61.6% |
| Selling, General & Admin | $1.75B 14.6% | $1.46B 13.3% | $1.14B 11.5% | $944.7M 10.6% | $840.1M 11.1% | $770.5M 12.4% | $658.5M 15.8% | $557.6M 18.3% | $496.1M 19.9% | $432.8M 25.4% |
| Total Operating Expenses | $7.83B 65.2% | $11.25B 102.1% | $6.04B 61.2% | $4.62B 51.8% | $4.79B 63.3% | $3.35B 54.0% | $2.97B 71.2% | $2.41B 79.2% | $2.37B 95.0% | $1.69B 99.4% |
| Operating Income | $4.17B 34.8% | -$232.9M -2.1% | $3.83B 38.8% | $4.31B 48.2% | $2.78B 36.7% | $2.86B 46.0% | $1.20B 28.8% | $635.1M 20.8% | $123.2M 5.0% | $9.9M 0.6% |
| Interest Expense | $13.3M 0.1% | $30.6M 0.3% | $44.1M 0.4% | $54.8M 0.6% | — | $58.2M 0.9% | $58.5M 1.4% | $72.5M 2.4% | $69.3M 2.8% | — |
| Other Income (Expense), net | -$7.7M -0.1% | -$86.1M -0.8% | -$22.8M -0.2% | -$164.8M -1.8% | $4.9M 0.1% | $296.6M 4.8% | $192.2M 4.6% | -$790K -0.0% | -$81.4M -3.3% | $4.1M 0.2% |
| Pretax Income | $4.64B 38.7% | $248.5M 2.3% | $4.38B 44.4% | $4.23B 47.4% | $2.73B 36.0% | $3.12B 50.2% | $1.39B 33.5% | $600.2M 19.7% | -$15.7M -0.6% | -$67.4M -4.0% |
| Income Tax Expense | $690.0M 5.7% | $784.1M 7.1% | $760.2M 7.7% | $910.4M 10.2% | $388.3M 5.1% | $405.2M 6.5% | $218.1M 5.2% | -$1.49B -48.8% | -$107.3M -4.3% | $16.7M 1.0% |
| Net Income | $3.95B 32.9% | -$535.6M -4.9% | $3.62B 36.7% | $3.32B 37.2% | $2.34B 30.9% | $2.71B 43.7% | $1.18B 28.3% | $2.10B 68.8% | $263.5M 10.6% | -$112.1M -6.6% |
| Per Share | ||||||||||
| EPS (Basic) | $15.46 | $-2.08 | $14.05 | $12.97 | $9.09 | $10.44 | $4.58 | $8.24 | $1.06 | $-0.46 |
| EPS (Diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | $-0.46 |
| Weighted Avg Shares (Basic) | 255.7M | 257.9M | 257.7M | 256.1M | 257.7M | 259.8M | 256.7M | 254.3M | 248.9M | 244.7M |
| Weighted Avg Shares (Diluted) | 258.0M | 257.9M | 260.5M | 259.1M | 259.9M | 263.4M | 260.7M | 259.2M | 253.2M | 244.7M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
EOD close · as of 2026-09-17
No material risks flagged.
Where each multiple sits in its own 14-yr range · 54th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 13.4 | 13.2 | 11.9 | 11.9 | 12.1 | 12.8 | 13.9 | 13.8 |
| R&D | 46.5 | 42.1 | 29.5 | 40.3 | — | — | — | — |
| SG&A | 18.3 | 15.8 | 12.4 | 11.1 | 10.6 | 11.5 | 13.3 | 14.6 |
| Operating Income | 20.8 | 28.8 | 46.0 | 36.7 | 48.2 | 38.8 | -2.1 | 34.8 |
| Income Tax | -48.8 | 5.2 | 6.5 | 5.1 | 10.2 | 7.7 | 7.1 | 5.7 |
| Net Income | 68.8 | 28.3 | 43.7 | 30.9 | 37.2 | 36.7 | -4.9 | 32.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on VRTX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
Peers = companies sharing VRTX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.